SEC Tracker
Get the app

Viracta Therapeutics

Viracta Therapeutics: signs a material agreement and says a debt obligation was accelerated

Form
8-K
Filed
Period
Importance
Major
Document
8-K
Exhibit 10.1
Material contract
  • Signs a material agreement (1.01)
  • Says a debt obligation was accelerated (2.04)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when Viracta Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.